Clinical Evaluation of Montelukast on Cognitive and Mood Dysfunction and Neuroinflammation in Veterans with Gulf War Illness (GWI)

Abstract

The chemical exposures implicated include the pyridostigmine bromide (PB) pills consumed daily during the war to protect against nerve gas and pesticides that included the insecticide permethrin (PER) and insect repellant N, N-diethyl-m-toluamide (DEET). The chemical exposures combined with the war-related stress are thought to have produced the neurological symptoms frequently suffered by Veterans with GWI. This project will examine the pre-clinical promise of Montelukast (MLK) for improving neuroinflammation in veterans with GWI by assessing change in a novel peripheral blood marker of neuroinflammation. MLK, an FDA-approved drug for asthma, has shown efficacy in an animal model of GWI to improve cognitive and mood function through modulation of leukotriene signaling and suppression of neuroinflammation. This study will consist of sixty Gulf War Veterans of the U.S. military deployed on military orders to the Persian Gulf Region between August 2, 1990, and December 31, 1991. Participants will also need to meet criteria for GWI (both Kansas and CDC case definitions) with self-reported cognitive dysfunction based on testing.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2023
Accession Number
AD1218525

Entities

People

  • Drew A. Helmer

Organizations

  • Baylor College of Medicine

Tags

DTIC Thesaurus Topics

  • Alkenes
  • Alzheimer Disease
  • Biomedical Research
  • Clinical Trials
  • Cognitive Impairment
  • Department Of Defense
  • Dysfunction
  • Electronic Mail
  • Extracellular Vesicles
  • Gulfs
  • Information Operations
  • Instructors
  • Maryland
  • Persian Gulf Syndrome
  • Side Effects
  • Test And Evaluation
  • Universities

Readers

  • Gulf War Illness and Chronic Multisymptom Illness in Veterans.